Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients

11Citations
Citations of this article
35Readers
Mendeley users who have this article in their library.

Abstract

Objective: This post hoc analysis evaluated the efficacy and safety of triple therapy with amlodipine/valsartan+hydrochlorothiazide (Aml/Val+HCTZ) vs dual therapy with Aml+HCTZ in stage 2 hypertensive patients. Methods: The analysis included patients from an eight-week, multicenter, double-blind study, randomized to Aml/Val 10/160 mg or Aml 10 mg groups, who received add-on HCTZ 12.5 mg at week 4 if mean sitting systolic blood pressure (msSBP) was >130 mmHg. Results: Of the patients receiving Aml/Val+HCTZ and Aml+HCTZ, 98% (N = 133/136) and 96% (N = 200/208) completed the study, respectively. Baseline characteristics were similar across groups (Caucasians, 80.2%; diabetics, 14.8%; age, 58.6 years [28.2% ≥ 65 years]; body mass index, 31 kg/m 2; mean sitting blood pressure (msBP), 171.5/95.5 mmHg [18% msSBP ≥ 180 mmHg]). Aml/Val+HCTZ provided significantly greater msBP reductions from baseline to week 8 than Aml+HCTZ (30.5/13.8 vs 24.3/8.3 mmHg, P < 0.0001). The incremental msBP reduction (week 4 to 8) with HCTZ added to Aml/Val was greater than when added to Aml (6.9/3.5 vs 3.1/1.0 mmHg, P<0.01). Treatments were well tolerated with similar overall incidence of adverse events (Aml/Val+HCTZ: 33.8%, Aml+HCTZ: 33.2%). Conclusion: Aml/Val+HCTZ provided signifcantly greater BP reductions than Aml+HCTZ in patients with stage 2 hypertension. Aml/Val+HCTZ triple therapy may be a suitable option for patients requiring more than two agents to reach target BP. © 2010 Destro et al, publisher and licensee Dove Medical Press Ltd.

References Powered by Scopus

The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report

17302Citations
N/AReaders
Get full text

Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients

1863Citations
N/AReaders
Get full text

Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial

1773Citations
N/AReaders
Get full text

Cited by Powered by Scopus

The efficacy and safety of triple vs dual combination of angiotensin ii receptor blocker and calcium channel blocker and diuretic: A systematic review and meta-analysis

28Citations
N/AReaders
Get full text

Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy

11Citations
N/AReaders
Get full text

Effects of valsartan versus olmesartan addition to amlodipine/ hydrochlorothiazide combination in treating stage 2 hypertensive patients

7Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Destro, M., Crikelair, N., Yen, J., & Glazer, R. (2010). Triple combination therapy with amlodipine, valsartan, and hydrochlorothiazide vs dual combination therapy with amlodipine and hydrochlorothiazide for stage 2 hypertensive patients. Vascular Health and Risk Management, 6(1), 821–827. https://doi.org/10.2147/VHRM.S11522

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 15

71%

Researcher 5

24%

Lecturer / Post doc 1

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 14

74%

Computer Science 2

11%

Business, Management and Accounting 2

11%

Design 1

5%

Save time finding and organizing research with Mendeley

Sign up for free